Eric Rosenberg, MD
Infectious Disease · Boston, MANPI 1801877691
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $133,750 of the $133,750 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Modernatx, Inc.. Among infectious disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 6 payments — averaging $22,292 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$134K
Across 11 payments — averaging $71,523 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$787K
What the payments were for
- Consulting fees$133,750100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 6 | $133,750 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Moderna Covid-19 Vaccine$133,750
How this compares
$133,750 in reported general payments places this provider in the 95th percentile of 368 infectious disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $47,011 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Boston
- Yoav GolanBoston$1.1M
- Nesli BasgozBoston$901K
- Todd EllerinBoston$843K
- Paul SaxBoston$320K
- Davidson HamerBoston$221K
- Camille KottonBoston$195K
- David SnydmanBoston$141K
- Deborah HungBoston$130K
- Laura KogelmanBoston$54K
- Jay FishmanBoston$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.